Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Estech's AF (atrial fibrillation) ablation tools:

This article was originally published in Clinica

Executive Summary

The US FDA has given Estech 510(k) clearance to sell its Cobra line of products for the surgical treatment of atrial fibrillation (AF). The tools, which were also recently cleared for sale in Europe, comprise the Cobra Adhere radiofrequency ablation system and the Cobra bipolar pacing probe. The Adhere device is used to make lesions on the heart to block the electrical impulses that cause AF. The pacing probe provides a means for immediately evaluating the effectiveness of AF treatment procedures. According to the Danville, California firm, the Cobra technology is unique in that it uses an "intelligent temperature-based" system that provides both optimal and reproducible results by regulating the RF energy. "Other systems offered by AtriCure, Medtronic and Guidant do not have this advanced energy regulation technology," the company claimed.

You may also be interested in...

Lannett Plans Seven Launches In Fiscal Year 2021

Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020. 

Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.

A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts